Logo

American Heart Association

  2
  0


Final ID: MDP886

Pattern of Disease Progression in ATTR-CM Patients Treated with Tafamidis: An Observational Study

Abstract Body (Do not enter title and authors here): Background: Consensus on a definition of disease progression in transthyretin amyloid cardiomyopathy (ATTR-CM) is lacking. Recent data showed that among a large cohort 50% of patients progressed as defined by either N-terminal pro-B type natriuretic peptide (Nt-proBNP) increase of 700 pg/ml AND 30% or increase of oral diuretics (ODI) after 1 year. However, most of the patients were not on disease modifying treatment (DMT).
Aim: To describe the pattern of progression at 1 year in patients with ATTR-CM on tafamidis, the only approved drug for ATTR-CM.
Methods: Patients diagnosed with ATTR-CM at Columbia University and treated with tafamidis after 2018 were enrolled in the study assuming they survived a year to measure disease progression and had data available at follow-up. A total of 16 patients died before the 1-year follow-up and were excluded from the study. Disease progression was defined as: increase in Nt-proBNP>700 pg/mL and >30% from baseline, ODI or increases in both compared to baseline. Survival analysis was done using Kaplan Meier curves and Cox regression adjusted for age and disease severity by National Amyloidosis Center stage.
Results: A total of 157 patients were enrolled, with 62 (39.5%) having disease progression at 1-year. Of these 62 patients, 51 met one progression criterion (34 patients had ODI and 17 had NtproBNP increase), with 11 having both criteria of disease progression at 1 year. Survival analysis revealed a significantly increased risk for all-cause mortality during follow-up in patients with disease progression at 1-year (HR=2.13, 95%CI:1.04-4.35, p=0.03, Figure).
Conclusion: The recently proposed criteria for disease progression performed well in a cohort of patients on DMT, which may reduce the number of patients progressing at 1 year.
  • Bampatsias, Dimitrios  ( Columbia University Medical Center , New York , New York , United States )
  • Wardhere, Abdirahman  ( Columbia University Medical Center , New York , New York , United States )
  • Zeldin, Lawrence  ( Columbia University Medical Center , New York , New York , United States )
  • Mirabal, Alfonsina  ( Columbia University Medical Center , New York , New York , United States )
  • Weinsaft, Ariel  ( Columbia University Medical Center , New York , New York , United States )
  • Smiley, Dia  ( Columbia University Medical Center , New York , New York , United States )
  • Teruya, Sergio  ( Columbia University Medical Center , New York , New York , United States )
  • Maurer, Mathew  ( Columbia University Medical Center , New York , New York , United States )
  • Author Disclosures:
    Dimitrios Bampatsias: DO NOT have relevant financial relationships | Abdirahman Wardhere: No Answer | Lawrence Zeldin: No Answer | Alfonsina Mirabal: DO NOT have relevant financial relationships | Ariel Weinsaft: No Answer | Dia Smiley: No Answer | Sergio Teruya: DO NOT have relevant financial relationships | Mathew Maurer: DO have relevant financial relationships ; Advisor:Intellia:Active (exists now) ; Advisor:Alnylam:Active (exists now) ; Advisor:Ionis:Active (exists now) ; Advisor:Bridge Bio:Active (exists now) ; Advisor:AZ:Active (exists now) ; Advisor:Novo Nordisk:Active (exists now)
Meeting Info:

Scientific Sessions 2024

2024

Chicago, Illinois

Session Info:

Unfolding Updates in Transthyretin Cardiac Amyloidosis

Sunday, 11/17/2024 , 11:10AM - 12:35PM

Moderated Digital Poster Session

More abstracts on this topic:
Abrupt cardiac rupture of the patient with ATTR amyloidosis

Tagata Kento, Yutaro Nomoto, Tao Koji, Kataoka Tetsuro, Ohishi Mitsuru

A Stepwise Approach to Identifying and Assessing the Content Validity of Patient-Reported Outcome (PRO) Measures for Use with Adults with Acute Heart Failure

O'connor Meaghan, Loughlin Anita, Waldman Laura, Rucker Sloan, Vaghela Shailja, Kwon Namhee, Sikirica Vanja

More abstracts from these authors:
Short Physical Performance Battery as a Marker of Severity and Predictor of Clinical Outcomes in Transthyretin Amyloid Cardiomyopathy (ATTR-CM)

Dershowitz Lyle, Teruya Sergio, Bampatsias Dimitrios, Wardhere Abdirahman, Mirabal Alfonsina, Santana Del Rosario Denisse, Maurer Mathew

5 Key Lessons learned about Cardiac Amyloidosis in the last 10 years and what remains to be learned. 10 minutes

Maurer Mathew, Ambardekar Amrut

You have to be authorized to contact abstract author. Please, Login
Not Available